Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxychloroquine

B Potter1

  • 1Medical Group of Michigan City Professional Corporation, Indiana.

Cutis
|October 1, 1993
PubMed
Summary
This summary is machine-generated.

Hydroxychloroquine (Plaquenil) is the sole FDA-approved lupus drug. Retinal toxicity risk is minimal with doses under 6 mg/kg/day and regular eye exams, making it generally safe for lupus treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

Canadian journal of surgery. Journal canadien de chirurgie·2025
Same author

The role of mediating verbal behavior in selection-based responding.

The Analysis of verbal behavior·2012
Same author

A review of studies examining the nature of selection-based and topography-based verbal behavior.

The Analysis of verbal behavior·2012
Same author

Some additional considerations of protocol analyses.

The Analysis of verbal behavior·2012
Same author

Attitude and knowledge about genetics and genetic testing.

Public health genomics·2009
Same author

Canada: public health genomics.

Public health genomics·2008
Same journal

Black Dots on the Scalp of a Child.

Cutis·2026
Same journal

Psoriasis and Obesity: A Clinical Review of the Bidirectional Link and Management Implications.

Cutis·2026
Same journal

Adalimumab in Lichen Planus: A Narrative Review of Treatment and Paradoxical Reactions.

Cutis·2026
Same journal

The Future of Psoriasis Care.

Cutis·2026
Same journal

Evaluating GPT-4o for Automated Classification of Skin Lesions Using the HAM10000 Dataset.

Cutis·2026
Same journal

Metastatic Primary Extramammary Paget Disease: A Case Series.

Cutis·2026
See all related articles

Area of Science:

  • Rheumatology
  • Ophthalmology
  • Pharmacology

Background:

  • Hydroxychloroquine (Plaquenil) is the only FDA-approved antimalarial drug for lupus erythematosus.
  • Official dosage recommendations for lupus treatment are not well-defined.

Purpose of the Study:

  • To evaluate the risk-benefit ratio of hydroxychloroquine in lupus treatment.
  • To establish safe dosage guidelines and monitoring protocols to prevent ocular toxicity.

Main Methods:

  • Review of existing literature on hydroxychloroquine dosage and retinopathy.
  • Analysis of ocular risk factors, including dose/weight ratio and duration of therapy.
  • Assessment of the efficacy of regular ophthalmologic examinations.

Main Results:

Related Experiment Videos

  • Retinopathy is associated with prolonged use (over six months) or high cumulative doses (over 72 gm) or daily doses exceeding 200 mg.
  • Ocular risk is negligible at doses below 6 mg/kg/day.
  • A daily dose of 400 mg or more is acceptable for average-weight individuals with adequate monitoring.

Conclusions:

  • The risk of retinal toxicity from hydroxychloroquine is dose and duration-dependent.
  • Regular ophthalmologic monitoring every six months is crucial for early detection of adverse reactions.
  • Hydroxychloroquine can be safely used in lupus patients when prescribed within recommended dosage limits and with appropriate monitoring.